[O-17] Oral Session 17 Neuromuscular junction disorders

[O-17-4] Eculizumab treatment in gMG patient in Japan: interim report from post-marketing surveillance

^○Kimiaki Utsugisawa¹, Shigeaki Suzuki², Takeshi Hayashi³, Yuji Fukamizu³, Murai Hiroyuki⁴ (1.Department of Neurology, Hanamaki General Hospital, Japan, 2.Department of Neurology, Keio University School of Medicine, 3.Medical Affairs, Alexion Pharma GK, 4.Department of Neurology, International University of Health and Welfare)